RaySearch Laboratories AB (27R) AI Stock Analysis

RaySearch Laboratories AB

(Frankfurt:27R)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong cash generationRobust operating and free cash flow gives RaySearch capacity to fund product development, customer implementations and market expansion internally. Strong cash conversion also improves resilience through uneven license cycles, while reducing dependence on external financing for ongoing strategic investment.

Negative Factors

Recent revenue and margin contractionThe weak quarter shows that RaySearch's earnings remain exposed to timing and volume fluctuations in license-driven sales. Lower revenue and margin reduce operating leverage, and repeated softness would make it harder to sustain profitability while continuing investment in products and market development.

RaySearch Laboratories AB (27R) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 602.69M
Dividend Yield: 1.62%
Average Volume (3M): 381
Price to Earnings (P/E): 31.7
Beta (1Y): 1.15
Revenue Growth: 4.76%
EPS Growth: 14.28%
Country: Germany
Employees: 464
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Healthcare Information Services

RaySearch Laboratories AB Business Overview & Revenue Model

Company Description

RaySearch Laboratories AB (publ) is a global medical technology company dedicated to developing cutting-edge software solutions for cancer treatment. Its principal offering, RayStation, is a sophisticated treatment planning system that supports a vas...

RaySearch Laboratories AB Earnings Call Summary

Earnings Call Date:Nov 02, 2026(Q3-2026)|Next Earnings Date:Aug 12, 2026

Earnings Call SentimentPositive

The call was predominantly positive, supported by record Q3 sales, strong order intake, U.S. momentum, strategic customer wins, expanding RayCare adoption, substantial backlog and strong financial flexibility. However, license sales declined, margins were pressured by an unusually high hardware mix, free cash flow was negative, RayCare deal conversion remains gradual, reimbursement-related delays persist, and the full-year EBIT target requires an exceptionally strong fourth quarter.

Positive Updates

Broad Platform Reach and Patient Impact

RaySearch has four software platforms—RayStation, RayCare, RayIntelligence and RayCommand—480 employees across 31 nationalities, 26 industrial partners, and 1,248 clinics in 54 countries using RayStation. The company's software has been used to treat over 11 million cancer patients.

Negative Updates

Quarterly Growth Fluctuation

Management noted a slight decline in the Q3 portion of its recent performance trend, although it still expects growth for the full year of 2026.

Company Guidance

RaySearch expects growth to continue for the full year of 2026 and also expects a very strong end of 2026, with Q4 traditionally its strongest quarter; management said it will be “a stellar Q4” to achieve the full year EBIT margin target of at least 25%, which “remains within reach,” is “not a given” but “reasonable,” and excludes costs related to the long-term incentive program introduced in the second quarter this year. Management expects a few more RayCare orders this year, said RayCare will contribute in 2027, expects customer receivables to remain at the same high numbers in the next quarter but not increase further, and expects sales and marketing costs to be on about the same level in the next quarter as in this.

RaySearch Laboratories AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:27R against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:SECT.B	74Outperform	SEK 67.51B	101.10	30.26%	0.38%	13.94%	5.70%
SE:SUS	69Neutral	SEK 3.00B	32.21	―	―	8.40%	0.74%
SE:PAX	60Neutral	SEK 1.54B	-292.39	-1.22%	―	34.05%	-144.96%
SE:MNTC	58Neutral	SEK 435.95M	-91.65	-3.61%	―	15.87%	92.43%
SE:CRAD.B	56Neutral	SEK 783.39M	16.70	13.23%	0.43%	-8.76%	103.87%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:27R and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:27R	RaySearch Laboratories AB Class B	18.09	-2.03	-10.08%
SE:PAX	Paxman AB	63.80	-2.40	-3.63%
SE:CRAD.B	C-Rad AB Class B	23.50	-9.40	-28.57%
SE:SECT.B	Sectra AB Class B	330.60	36.35	12.35%
SE:MNTC	Mentice AB	15.70	6.30	67.02%
SE:SUS	Surgical Science Sweden AB	58.95	-24.45	-29.32%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

RaySearch Laboratories AB AI Stock Analysis